Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 636 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control gel Clear all
Completed Not applicable Interventional

Vaginal Care System for Menopausal Women With Urinary Tract Infections

NCT05573334
View directory record Official record
Conditions
Urinary Tract Infections, Vaginal Flora Imbalance
Interventions
BioNourish
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
Up to 89 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

NCT00713609
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide gel, Clindamycin gel, Tazarotene cream, Vehicle gel, Vehicle cream
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03986905
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine Nasal Gel, Placebo
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Smart Olfaction App to Reduce Relapse

NCT07007195
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Ad Libitum Use followed by Instructed Use of the Inspire Device, Instructed Use followed by Ad Libitum Use of the Inspire Device, Smart-T Smoking Cessation App with the Inspire Device Condition, Smart-T Smoking Cessation App Without the Inspire Device Condition, Nicotine replacement therapy (NRT), Inspire Device
Device · Drug
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)

NCT03362957
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Geniculate Artery Embolization, Sham Procedure
Device · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 4 Interventional Results available

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

NCT02769702
View directory record Official record
Conditions
Uveitis
Interventions
Acthar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics

NCT01612156
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
2% lidocaine gel, Water based lubricant
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
View directory record Official record
Conditions
Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

NCT04029545
View directory record Official record
Conditions
Lip Augmentation
Interventions
PN40082
Device
Lead sponsor
Prollenium Medical Technologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
5
States / cities
Encinitas, California • Miami, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

NCT01613131
View directory record Official record
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of PN40082 for Lip Augmentation

NCT04032977
View directory record Official record
Conditions
Lip Augmentation
Interventions
PN40082, Restylane Silk
Device
Lead sponsor
Prollenium Medical Technologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Study of Bimatoprost Gel on Eyelash Growth

NCT01200251
View directory record Official record
Conditions
Madarosis, Hypotrichosis
Interventions
Bimatoprost eyelash gel
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects

NCT02509845
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

NCT00243789
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Pentoxifylline
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
7 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

NCT00382174
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Placebo, Thymosin Beta 4
Drug
Lead sponsor
RegeneRx Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Montgomery, Alabama • Beverly Hills, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
prasterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
280
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse

NCT01024738
View directory record Official record
Conditions
Dental Plaque
Interventions
Fluoride, Triclosan, fluoride, Chlorhexidine Gluconate
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

NCT02682238
View directory record Official record
Conditions
Hyperhidrosis
Interventions
BBI-4000, 15%, Vehicle gel
Drug · Other
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Carmel, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

NCT03850964
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed, HHT
Interventions
Pazopanib, Placebo oral capsule
Drug
Lead sponsor
Cure HHT
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

NCT05446584
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
Interventions
High Definition Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 22, 2026, 5:25 AM EDT